# Northwestern University: Phase 2 study started recruiting, 125 planned (Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Northwestern University |
| Sponsor type | Academic and hospital |
| Study | SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial |
| NCT ID | NCT07748611 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma |
| Intervention types | procedure, other, drug, radiation |
| Target enrollment | 125 |
| Site countries | United States |
| Posted | 2026-08-06 |
| Planned start | 2026-10-26 |
| Event | Started recruiting |
| Event date | 2026-10-26 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.
- 125 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07748611). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.